Clinical trial
Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney…
NCT00123461 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00123461 |
|---|---|
| Title | Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism |
| Official title | A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in Vitamin D-replete Subjects With Chronic Kidney Disease (CKD) Stages 3 or 4 With Secondary Hyperparathyroidism (SHPT). |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Secondary Hyperparathyroidism, Renal Failure, Chronic Renal Insufficiency |
| Intervention type | Drug |
| Interventions | Hectorol (doxercalciferol capsules), 0.5mcg |
| Enrollment | 70 |
| Start date | Jul 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Jul 25, 2005 |
| Last update posted | May 5, 2015 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: